Meeting Report: Vaccine Stability Considerations to Enable Rapid Development and Deployment

Abstract The Stability Community of the American Association of Pharmaceutical Scientists (AAPS) held a virtual workshop on “Vaccine Stability Considerations to Enable Rapid Development and Deployment”, on March 24-25, 2021. The workshop included distinguished speakers and panelists from across the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mark Alasandro, Dilip Choudhury, Kim Huynh-Ba, Jianmei Kochling, Christopher Latoz, Laure Larkin, Lori McCaig, Nanda Subbarao, Yan Wu, Yajie Zhang
Formato:	article
Lenguaje:	EN
Publicado:	SpringerOpen 2021
Materias:	Vaccine Development COVID-19 Stability Rapid Development Rapid Deployment Last-Mile Therapeutics. Pharmacology RM1-950 Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/a1c20c01b5e340cdb6cab242725d2254
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a1c20c01b5e340cdb6cab242725d2254
record_format	dspace
spelling	oai:doaj.org-article:a1c20c01b5e340cdb6cab242725d22542021-12-05T12:11:04ZMeeting Report: Vaccine Stability Considerations to Enable Rapid Development and Deployment10.1186/s41120-021-00042-12364-9534https://doaj.org/article/a1c20c01b5e340cdb6cab242725d22542021-12-01T00:00:00Zhttps://doi.org/10.1186/s41120-021-00042-1https://doaj.org/toc/2364-9534Abstract The Stability Community of the American Association of Pharmaceutical Scientists (AAPS) held a virtual workshop on “Vaccine Stability Considerations to Enable Rapid Development and Deployment”, on March 24-25, 2021. The workshop included distinguished speakers and panelists from across the industry, academia, regulatory agencies, as well as health care leaders. This paper presents a review of the topics covered. Specifically the challenges in accelerating vaccine development and analytical characterization techniques to establish shelf-life were covered. Additionally, vaccine stability modeling using prior knowledge stability models and advanced kinetic analysis played a key in the EUA approaches discussed during the workshop. Finally, the role of stability studies in addressing the challenges of vaccine distribution and deployment during the pandemic were a focus of presentations and panel discussions. Although the workshop did not have any presentation topics directly dedicated to the mRNA vaccines, the techniques discussed are generally applicable. The mRNA vaccine developers were represented in the panel discussions, where experts involved in the EUA approval/deployment stages for this vaccine type could discuss the challenges as applied to their vaccines.Mark AlasandroDilip ChoudhuryKim Huynh-BaJianmei KochlingChristopher LatozLaure LarkinLori McCaigNanda SubbaraoYan WuYajie ZhangSpringerOpenarticleVaccine DevelopmentCOVID-19StabilityRapid DevelopmentRapid DeploymentLast-MileTherapeutics. PharmacologyRM1-950Pharmacy and materia medicaRS1-441ENAAPS Open, Vol 7, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Vaccine Development COVID-19 Stability Rapid Development Rapid Deployment Last-Mile Therapeutics. Pharmacology RM1-950 Pharmacy and materia medica RS1-441
spellingShingle	Vaccine Development COVID-19 Stability Rapid Development Rapid Deployment Last-Mile Therapeutics. Pharmacology RM1-950 Pharmacy and materia medica RS1-441 Mark Alasandro Dilip Choudhury Kim Huynh-Ba Jianmei Kochling Christopher Latoz Laure Larkin Lori McCaig Nanda Subbarao Yan Wu Yajie Zhang Meeting Report: Vaccine Stability Considerations to Enable Rapid Development and Deployment
description	Abstract The Stability Community of the American Association of Pharmaceutical Scientists (AAPS) held a virtual workshop on “Vaccine Stability Considerations to Enable Rapid Development and Deployment”, on March 24-25, 2021. The workshop included distinguished speakers and panelists from across the industry, academia, regulatory agencies, as well as health care leaders. This paper presents a review of the topics covered. Specifically the challenges in accelerating vaccine development and analytical characterization techniques to establish shelf-life were covered. Additionally, vaccine stability modeling using prior knowledge stability models and advanced kinetic analysis played a key in the EUA approaches discussed during the workshop. Finally, the role of stability studies in addressing the challenges of vaccine distribution and deployment during the pandemic were a focus of presentations and panel discussions. Although the workshop did not have any presentation topics directly dedicated to the mRNA vaccines, the techniques discussed are generally applicable. The mRNA vaccine developers were represented in the panel discussions, where experts involved in the EUA approval/deployment stages for this vaccine type could discuss the challenges as applied to their vaccines.
format	article
author	Mark Alasandro Dilip Choudhury Kim Huynh-Ba Jianmei Kochling Christopher Latoz Laure Larkin Lori McCaig Nanda Subbarao Yan Wu Yajie Zhang
author_facet	Mark Alasandro Dilip Choudhury Kim Huynh-Ba Jianmei Kochling Christopher Latoz Laure Larkin Lori McCaig Nanda Subbarao Yan Wu Yajie Zhang
author_sort	Mark Alasandro
title	Meeting Report: Vaccine Stability Considerations to Enable Rapid Development and Deployment
title_short	Meeting Report: Vaccine Stability Considerations to Enable Rapid Development and Deployment
title_full	Meeting Report: Vaccine Stability Considerations to Enable Rapid Development and Deployment
title_fullStr	Meeting Report: Vaccine Stability Considerations to Enable Rapid Development and Deployment
title_full_unstemmed	Meeting Report: Vaccine Stability Considerations to Enable Rapid Development and Deployment
title_sort	meeting report: vaccine stability considerations to enable rapid development and deployment
publisher	SpringerOpen
publishDate	2021
url	https://doaj.org/article/a1c20c01b5e340cdb6cab242725d2254
work_keys_str_mv	AT markalasandro meetingreportvaccinestabilityconsiderationstoenablerapiddevelopmentanddeployment AT dilipchoudhury meetingreportvaccinestabilityconsiderationstoenablerapiddevelopmentanddeployment AT kimhuynhba meetingreportvaccinestabilityconsiderationstoenablerapiddevelopmentanddeployment AT jianmeikochling meetingreportvaccinestabilityconsiderationstoenablerapiddevelopmentanddeployment AT christopherlatoz meetingreportvaccinestabilityconsiderationstoenablerapiddevelopmentanddeployment AT laurelarkin meetingreportvaccinestabilityconsiderationstoenablerapiddevelopmentanddeployment AT lorimccaig meetingreportvaccinestabilityconsiderationstoenablerapiddevelopmentanddeployment AT nandasubbarao meetingreportvaccinestabilityconsiderationstoenablerapiddevelopmentanddeployment AT yanwu meetingreportvaccinestabilityconsiderationstoenablerapiddevelopmentanddeployment AT yajiezhang meetingreportvaccinestabilityconsiderationstoenablerapiddevelopmentanddeployment
_version_	1718372209632739328

Meeting Report: Vaccine Stability Considerations to Enable Rapid Development and Deployment

Ejemplares similares